To date, even if XMRV involvement in prostate cancer and CFS appear to be controversial, the eradication of XMRV appears to be a good strategy for the disease treatment

Pub. No.: WO/2011/092199 International Application No.: PCT/EP2011/051062 Publication Date: 04.08.2011 International Filing Date: 26.01.2011 IPC: C07K 14/15 (2006.01), A61K 38/16 (2006.01), C12N 7/04 (2006.01)

  Inventors: HEIDMANN, Thierry; (FR)., SCHLECHT-LOUF, Géraldine; (FR) Applicants: INSTITUT GUSTAVE ROUSSY [FR/FR]; 39, rue Camille Desmoulins F-94805 Villejuif Cedex (FR) (For All Designated States Except US). CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE [FR/FR]; 3, rue Michel-Ange F-75794 Paris (FR) (For All Designated States Except US). UNIVERSITE PARIS-SUD XI [FR/FR]; 15, rue Georges Clémenceau F-91405 Orsay Cedex (FR) (For All Designated States Except US). HEIDMANN, Thierry [FR/FR]; (FR) (For US Only). SCHLECHT-LOUF, Géraldine [FR/FR]; (FR) (For US Only). VIROXIS S.A.S. [FR/FR]; 11, rue Edouard Detaille F-75017 Paris (FR) (For All Designated States Except US) Inventors: HEIDMANN, Thierry; (FR). SCHLECHT-LOUF, Géraldine; (FR) Agent: GROSSET-FOURNIER, Chantal; 54, rue Saint-Lazare F-75009 Paris (FR)

 27 XMRV variants were filed in Genbank on September 11th, including this one, for which a patent was applied for: MUTATED XMRV ENV PROTEINS IN THE IMMUNOSUPPRESSIVE DOMAIN

So, to date, even if XMRV involvement in prostate cancer and CFS appear to be controversial, the eradication of XMRV appears to be a good strategy for the disease treatment.

 So, there is a need to provide an efficient drug in order to prevent and/or eradicate XMRV-infection associated diseases, an having an improved efficiency. One aim of the invention is to provide a new mutated attenuated virus, having enhanced vaccinal efficiency.

 Another aim of the invention is to provide a new pharmaceutical composition for treating pathologies. The present invention relates to a mutated XMRV ENV protein in which the immunosuppressive domain of the wild type XMRV ENV protein presents at least one mutation, said immunosuppressive domain of the wild type XMRV ENV protein consisting of the amino acid sequence SEQ ID NO : 1, (LQNRRGLDILFLKEGGLC AA) , said at least one mutation being such that E which is at the position 14 of SEQ ID NO : 1 is substituted by R, H or K. The present invention is based on the unexpected observation made by the Inventors that mutation in the immunosuppressive domain of XMRV ENV protein both - substantially, and in particular totally, abolish the immunosuppressive properties of XMRV ENV protein, and does not affect the three-dimensional structure of XMRV ENV protein, i.e. the resulting mutated XMRV ENV protein retains its structure and its antigenicity. Read more>>